Post-hypotensive Syndrome after Hypertension Treated by Nipiendipine Concerted with Chinese Traditional Drugs, observation on 44 cases

doi:10.13288/j.11-2166/r.2000.04.025

您当前的位置：

首页 >

文章列表页 >

Post-hypotensive Syndrome after Hypertension Treated by Nipiendipine Concerted with Chinese Traditional Drugs, observation on 44 cases

更新时间：2021-11-20

- Post-hypotensive Syndrome after Hypertension Treated by Nipiendipine Concerted with Chinese Traditional Drugs, observation on 44 cases
- Journal of Traditional Chinese Medicine Issue 4, Pages: 224-225(2000)
- 作者机构：
  
  1. 福建中医学院
  2. 福建中医学院附属人民医院
  3. 福建中医学院附属人民医院福建省福州市五四北路,350003
  4. 福建中医学院福建中医学院附属人民医院福建中医学院附属人民医院福建省福州市五四北路,350003
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2000.04.025
  CLC： R544.1
- Published：2000
- 稿件说明：
移动端阅览
[1]关冬梅,林孝正,李齐黝,赵新,林松波.中药配合尼群地平治疗高血压降压后综合征44例临床观察[J].中医杂志,2000(04):224-225+196.

Post-hypotensive Syndrome after Hypertension Treated by Nipiendipine Concerted with Chinese Traditional Drugs, observation on 44 cases[J]. Journal of Traditional Chinese Medicine2000, (4): 224-225.
[1]关冬梅,林孝正,李齐黝,赵新,林松波.中药配合尼群地平治疗高血压降压后综合征44例临床观察[J].中医杂志,2000(04):224-225+196. DOI： 10.13288/j.11-2166/r.2000.04.025.

Post-hypotensive Syndrome after Hypertension Treated by Nipiendipine Concerted with Chinese Traditional Drugs, observation on 44 cases[J]. Journal of Traditional Chinese Medicine2000, (4): 224-225. DOI： 10.13288/j.11-2166/r.2000.04.025.

摘要

观察补气补血中药合尼群地平治疗高血压降压后综合征临床疗效。将83例高血压病患者分为治疗组和尼群地平对照组

治疗前后分别测定心功能、血糖、血清胰岛素定量

24小时动态血压（ABPM）。并就临床主要症状按轻重评分累计判定

用以判定疗效与副反应

结果治疗组改善临床症状明显

累计积分较对照组差异有非常显著性（P<0.01）;两组均能改善胰岛素抵抗;治疗组治疗后射血分数（EF）及舒张早期减速度（DC）显著提高（P<0.01或P<0.05）

等容舒张时间（IRT）则显著降低;治疗组改善收缩压（SBP）负荷较对照组差异有非常显著性（P<0.01）。证明中药与尼群地平合用有防治、降压后综合征的作用

且无明显毒副作用。

Abstract

The clinical effect of nitrendipine on " post - hypotensive syndrome" concerted with Chinese medicines of invigorating -qi and nourishing blood was observed

with nitrendipine alone as control. The heart function

blood sugar

serum insulin

24- hour ABPM were estimated for evaluation of its effect and side - effects before and after treatment. Results showed that the treatment group had obvious improvement in symptoms and accumulated scores with very significant difference when compared with that of the control group （P<0. 01） ; insulin -resistance was improved in both groups. The treatment group had marked elevation of DC

EF （P < 0. 05

P < 0. 01 respectively）. The SBP negative load in treatment group was very significantly different as compared with the control group（P<0. 01）

demonstrating that the combined use of both drugs yielded action of prevention and treatment in post -hypotensive syndrome without obvious side effects.

关键词

Keywords

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

LI Guolie's Experience in Treating Orthostatic Hypotension from the Perspective of "Raising the Clear and Directing the Turbid Downward"

Exploring the Comorbidity Mechanism，Prevention and Treatment Strategies of Rheumatoid Arthritis with Coronary Atherosclerotic Heart Disease Based on Collateral Disease Theory

Efficacy and Economic Evaluation of Weishi Qingjin Formula （苇石清金方）in the Treatment of Adult Community-Acquired Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome：A Multicenter Retrospective Real-World Cohort Study

Clinical Efficacy and Economic Evaluation of 1293 Non-Severe Adult Patients with Community-Acquired Pneumonia Treated by the Jiangsu Traditional Chinese Medicine Diagnosis and Treatment Protocol for Dominant Diseases：A Multicenter，Retrospective Real-World Cohort Study

Construction and Application of "Source-Pivot-Convergence" Pattern Identification and Treatment Model for Malignant Tumors

Related Author

No data

Related Institution

No data

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰